The Daily Papule

Meeting abstracts

BAD 2026

British Association of Dermatologists · Manchester, 30 June – 2 July 2026

639 abstracts, published in BJD on 26 June 2026.

  1. BG07

    Three cases of biologic-associated interstitial lung disease

    Bowe S, Kiely J, … senior author Bourke J

  2. BG09

    The skin–brain axis: exploring the role of neuroinflammation in dermatological and neurological disorders

    Su Huey AK, Uzun M, … senior author Uwishema O

  3. BH05

    Eighteen years’ experience of grenz ray therapy for the treatment of nail disorders: a single-centre retrospective study

    Eloofy M, Rokia M, … senior author Dawe R

  4. BH06

    Monitoring of nail psoriasis with optical coherence tomography under treatment with tildrakizumab for 52 weeks

    Hobelsberger S, Schmirler S, … senior author Beissert S

  5. BH16

    Early-onset onychodysplasia with multisystem ectodermal features in a toddler: a diagnostic challenge

    Ahmed H, Constantinou S, … senior author Takwale A

  6. BH17

    A case of onychotillomania triggered by underlying inflammatory nail disorder

    Haqiqi A, Ting J, Cousen P

  7. BI09

    Risk of skin cancer in solid organ transplant recipients prescribed biologics for psoriasis

    Ray R, Chin N, Yu J

  8. BI12

    Two skin diseases, one checkpoint inhibitor: cutaneous toxicity from pembrolizumab

    Tan XL, Goiriz R, … senior author Harwood C

  9. BI38

    Methotrexate-associated lymphoma in atopic dermatitis: two case reports

    Eid D, Ponnambath N

  10. BSV01

    Anogenital psoriasis: an inclusive literature review with clinician survey data demonstrating current clinical awareness and practices with subsequent patient-focused feasibility studies for real-world experiences and outcomes

    Patel P, Stavrou C, … senior author Millette D

  11. BSV05

    Vulval lichen simplex and markers of anaemia and vitamin D deficiency in an ethnically diverse population

    Mitchell S, Haddad S, … senior author Ekeowa-Anderson A

  12. DP15

    A case series of four patients with elastosis perforans serpiginosa with differing predisposing factors

    Doyle C, Timoney I, … senior author O’Connor C

  13. DP28

    The diagnostic challenge of distinguishing generalized pustular psoriasis from acute generalized exanthematous pustulosis

    Thanikachalam N, Rashid S, Grant L

  14. GD12

    Tinea indotineae complicating and potentially propagated by psoriasis

    Illango A, Montgomery R, … senior author Muinonen-Martin A

  15. HX17

    The fortunate side effect: serendipity and therapeutic innovation in dermatology

    Boyle A, Walsh MC, … senior author Stanciu M

  16. O03

    Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: analysis of UK pharmacovigilance data and literature review

    Fattahi A, Salako K

  17. O04

    Using biologic therapies as first-line systemic treatment for psoriasis: a cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

    Phan DB, Laws P, … senior author Yiu Z

  18. O08

    The aryl hydrocarbon receptor pathway is differentially regulated in psoriasis and atopic dermatitis with implications for therapeutic intervention

    Dawe H, Ashoori MD, … senior author Di Meglio P

  19. O10

    Risk factors for incident and recurrent erythrodermic psoriasis: cohort analyses from the British Association of Dermatologists Biologics and Immunomodulators Register

    Al-Janabi A, Alabas O, … senior author Warren RB

  20. O11

    Model-informed precision dosing of biologic therapies in psoriasis: development, validation and clinical translation

    Wei R, Thomas C, … senior author Mahil S

  21. P004

    Digital dermatology: influence of online content on disease beliefs, anxiety and treatment behaviour in atopic dermatitis, topical steroid withdrawal and psoriasis

    Al-Temimi D, Bewley A, Gkini M

  22. P030

    A rash decision: refractory erythroderma as an atypical presentation of hypocomplementaemic urticarial vasculitis

    Victory L, Fagan N, … senior author Tobin AM

  23. P038

    Guselkumab for pembrolizumab-induced psoriasis in a patient with metastatic melanoma

    Conlon O, Herlihy M, … senior author O’Kane, Eilis Ni Chinneide, Helen Barrett and Adrian Murphy M

  24. P088

    Reasons for new patient attendances in general dermatology clinics in a secondary care service

    Aval LM, Patel NP

  25. P106

    A national survey exploring experiences of eczema, acne and psoriasis across different ethnic groups in the UK

    Hutchison E, Granell R, … senior author Ridd M

  26. P107

    Life expectancy, all-cause mortality and cause-specific mortality in psoriasis and generalized pustular psoriasis: a population-based cohort study in England

    Wright A, de Fátima Cobre A, … senior author Ashcroft D

  27. P113

    Is 3-monthly methotrexate monitoring necessary?

    Pallippattu AW, Anandbabu R, … senior author Yesudian PD

  28. P114

    The cost of caution: evaluating the utility and financial impact of procollagen-3 N - terminal peptide monitoring in methotrexate-treated patients

    Pallippattu AW, Anandbabu R, … senior author Yesudian PD

  29. P115

    Differential risk of incident psoriatic arthritis across immunomodulator classes used for psoriasis: a prospective cohort study

    Al-Janabi A, Alabas O, … senior author Warren RB

  30. P116

    Differential risk of incident and recurrent erythrodermic psoriasis in patients receiving systemic therapies: cohort analyses from the British Association of Dermatologists Biologics and Immunomodulators Register

    Al-Janabi A, Alabas O, … senior author Warren RB

  31. P122

    Real-world experience of tildrakizumab from a specialist dermatology department at a district hospital in the UK

    Barfoot M, Francis C, … senior author Schultz A

  32. P124

    Real-world effectiveness of guselkumab in moderate-to-severe plaque psoriasis with high-impact-site involvement: evidence from the British Association of Dermatologists Biologics and Immunomodulators Register

    Lloyd-Lavery A, El-Heis S, … senior author Jones H

  33. P125

    Hidden atherogenic risk in psoriasis: a case–control study using the Atherogenic Index of Plasma

    Alam S, Poonia K, … senior author Goyal G

  34. P138

    Retrospective real-world evaluation of Wynzora cream efficacy and safety

    Nayyar S, Patel B, … senior author Rashid S

  35. P140

    Cardiovascular footprints of psoriasis: insights from lipid indices and carotid intima–media thickness

    Alam S, Poonia K, … senior author Kaur H

  36. P141

    Maintaining disease control on systemic immunomodulatory therapy for psoriasis: a systematic review and meta-analysis

    Ye W, Corbett M, … senior author Mahil S

  37. P147

    Elevated incidence of autoimmune conditions in people with vitiligo: findings from a large contemporary English cohort

    Eleftheriadou V, Cook K, … senior author Ferguson J

  38. P156

    Real-world outcomes of secukinumab dose escalation in patients with plaque psoriasis weighing > 90 kg

    Broadhurst E, Mehrtens S

  39. P162

    Risks of tuberculosis, meningitis, candidiasis and fungal infections among patients receiving systemic treatments for psoriasis

    Bright Bright HR, Smith C, … senior author Yiu Z

  40. P163

    Serious infection risk of certolizumab compared with other systemic therapies in women with psoriasis

    Bright Bright HR, Smith C, … senior author Yiu Z

  41. P176

    ‘I didn’t want to be a darker shade of me’: a qualitative study exploring experiences of eczema, acne and psoriasis in people with skin of colour in the UK

    Hutchison E, Parslow R, … senior author Ridd M

  42. PA06

    Prescribing practices of methotrexate in a general paediatric dermatology department: a two-cycle retrospective audit (2018–2025)

    Aziz S, Shah S, … senior author Flohr C

  43. PD11

    Home phototherapy: one centre’s experience over the last 12 years

    Montgomery R, Britton J, Goulden V

  44. PD15

    Predicting psoriasis response to ultraviolet B phototherapy: how much do missed appointments and early treatment response impact outcome?

    Jand A, Arslan H, … senior author Weatherhead S

  45. PD20

    The impact of circadian rhythm on phototherapy treatment in psoriasis

    Tan YL, Armstrong V, … senior author Weatherhead S

  46. PS03

    The Dermatology Life Quality Index (DLQI) in 70 guidelines and 58 registries of 55 countries: a systematic review

    Johns J, Vyas J, … senior author Finlay AY

  47. PS10

    Walk and talk: connecting people with psoriasis. A prospective randomized controlled mixed-methods exploratory study to determine representativeness of recruitment, acceptability and feasibility of a walk-and-talk intervention for people with psoriasis

    Scheinmann P, McCann S, … senior author McBride S

  48. PS11

    A qualitative study on the views of adults with psoriasis regarding social media representation and awareness campaigns

    Toni E, Slater A, … senior author Guest E

  49. PS12

    Psycholag in moderate-to-severe psoriasis: insights from the POSITIVE study on psychological wellbeing and treatment with tildrakizumab

    Sommer R, Mrowietz U, … senior author Augustin M

  50. PS19

    Self-disgust and disgust sensitivity in individuals with atopic dermatitis and psoriasis

    Wülfing C, Lübke L, … senior author Spitzer C